<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bankhead, Charles</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Dorman, Susan E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluation of a Rifapentine-Containing Regimen for Intensive Phase Treatment of Pulmonary TB</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with sputum-positive tuberculosis had similar negative culture rates after 8 weeks of treatment with rifapentine or rifampin, according to results of the TBTC Study 29 [NCT00694629]. By solid media analysis, 91.4% of the rifapentine group and 89.1% of the rifampin group had negative cultures. By liquid media, the negative-culture rates were 74.6% with rifapentine and 70.1% with rifampin.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>